These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27090944)

  • 1. Is there any therapeutic value for the use of histone deacetylase inhibitors for chronic pain?
    Wang W; Cui SS; Lu R; Zhang H
    Brain Res Bull; 2016 Jul; 125():44-52. PubMed ID: 27090944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
    Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
    Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
    Chen PJ; Huang C; Meng XM; Li J
    Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylases as Potential Targets for Cocaine Addiction.
    Kennedy PJ; Harvey E
    CNS Neurol Disord Drug Targets; 2015; 14(6):764-72. PubMed ID: 26022264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roles of histone deacetylases in kidney development and disease.
    Liu H
    Clin Exp Nephrol; 2021 Mar; 25(3):215-223. PubMed ID: 33398599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HDACs: a promising therapy for Alzheimer's disease.
    Xu K; Dai XL; Huang HC; Jiang ZF
    Oxid Med Cell Longev; 2011; 2011():143269. PubMed ID: 21941604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration.
    Ganai SA; Ramadoss M; Mahadevan V
    Curr Neuropharmacol; 2016; 14(1):55-71. PubMed ID: 26487502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
    Collier CD; Getty PJ; Greenfield EM
    Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the correct HDAC(s) to treat cognitive disorders.
    Fischer A; Sananbenesi F; Mungenast A; Tsai LH
    Trends Pharmacol Sci; 2010 Dec; 31(12):605-17. PubMed ID: 20980063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation.
    Lkhagva B; Kao YH; Chen YC; Chao TF; Chen SA; Chen YJ
    Eur J Pharmacol; 2016 Jun; 781():250-7. PubMed ID: 27089819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlocking Macrophage Secrets: Histone Deacetylases in Chronic Transplant Rejection.
    Halasa M; Wawruszak A
    Results Probl Cell Differ; 2024; 74():297-313. PubMed ID: 39406911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of histone deacetylases (HDACs) in UPR regulation.
    Kahali S; Sarcar B; Chinnaiyan P
    Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs.
    Zhang W; Jiao B; Yu S; Zhang C; Zhang K; Liu B; Zhang X
    CNS Neurosci Ther; 2024 May; 30(5):e14745. PubMed ID: 38715326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA
    Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
    Weïwer M; Lewis MC; Wagner FF; Holson EB
    Future Med Chem; 2013 Sep; 5(13):1491-508. PubMed ID: 24024943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
    Pang M; Zhuang S
    J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.